{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000009","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.768445+00:00","generated_at":"2026-06-06T22:34:48.314966+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elicio presents ELI-002 7P Phase 1/2 trial design at ASCO GI; Phase 1A complete, Phase 2 enrolling","bullets":["Phase 1A completed with no dose-limiting toxicities; Phase 2 randomized 2:1 study enrolling PDAC patients.","ELI-002 7P targets seven KRAS mutations driving 25% of solid tumors using AMP lymph node-targeting platform.","First patient dosed in randomized Phase 2 cohort comparing ELI-002 7P to standard of care (observation).","Previous 2-peptide formulation published in Nature Medicine showed tumor biomarker reduction and reduced risk of relapse/death."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000009","json":"https://secwatch.observer/filing/0001601485-24-000009.json","markdown":"https://secwatch.observer/filing/0001601485-24-000009.md","text":"https://secwatch.observer/filing/0001601485-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000009/0001601485-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000009/angn-20240117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:34:48.314966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}